No abstract available.
Bone Density* ; Child* ; Humans

A new hypolipidemic drug, pravastatin, hydroxymethylglutaryl coenzyme A reductase inhibitor was administered to 33 patients with primary hyperlipidemia, 10mg daily for 8 weeks and sequential changes of lipid profile were analysed as follows. 1) Mean value at baseline period of total cholesterol, triglyceride, high and low density lipoprotein cholesterol were 260, 220, 51 and 163mg/dl respectively. 2) Total cholesterol showed 21% decrease at the end of 8 weeks and that of LDL-cholesterol were 30%. 3) Triglyceride decreased 16% at the end of 8 weeks and increment of HDL-cholesterol was 8% at the end of 8 weeks. 4) No serious side reactions were observed except one patient, who showed generalized skin rash which last 3 days and did not prevent further medication. In conclusion, pravastatin is a safe and useful hypolipidemic agent for the patient with primary hyperlipidemia.
Cholesterol ; Cholesterol, LDL ; Coenzyme A ; Exanthema ; Humans ; Hyperlipidemias* ; Oxidoreductases ; Pravastatin* ; Triglycerides

No abstract available.
Diabetes Insipidus, Nephrogenic* ; Urinary Tract Infections ; Vesico-Ureteral Reflux*

No abstract available.
Humans ; Temporomandibular Joint

Steatocystoma multiplex is a hamartomatous malformation of the pilosebaceous junction. It is thought to be hereditary or non-hereditary and rarely occurs on the face. We report a case of steatocystoma multiplex located only on the forehead of a 98-year-old woman. Histologic examination revealed a folded cyst wall consisting of several epithelial layers and flattened sebaceous gland lobules close to the cyst wall, which are relatively typical findings of steatocystoma multiplex.
Female ; Forehead* ; Humans ; Sebaceous Glands ; Steatocystoma Multiplex*

BACKGROUND/AIMS: There have been only few studies on the population-adjusted seroprevalence of HBV and HCV and on the change of them for more than 10 years in Korea. Therefore, this study was performed to evaluate them at a single health center in Daegu and Gyeongbuk province considering the population composition ratio. METHODS: We analyzed the seromarkers of HBV and HCV of 6,237 randomly sampled adults who had received health screening at the health promotion center in Dongsan hospital during the periods from year 1997 to 1999 (Period A) and from 2007 to 2009 (Period B). RESULTS: The seroprevalences of HBsAg, anti-HBs, anti-HBc and anti-HCV were 4.8%, 70.2%, 47.4%, and 0.5%, respectively. There is no difference in the seroprevalence of HBsAg between period A and B. However, downward tendency of prevalence through A to B from 6.8% to 4.5% could be found in 40s, and upward tendency from 4.7% to 6.8% in 50s. As for the seroprevalence of anti-HCV, although there was no difference through A to B, for 50s, it decreasd from 2.0% to 0.3% (p=0.007). However, for 60s, it increased as much as decreasd for 50s. CONCLUSIONS: The seroprevalence of HBsAg in Daegu/Gyeongbuk province was 4.8% and showed no difference through the time period of 10 years. The seroprevalence of anti-HCV was 0.5% and also showed no difference through the time periods.
Adult ; Aged ; Female ; Hepatitis B/*epidemiology ; Hepatitis B Antibodies/*blood ; Hepatitis B Surface Antigens/*blood/immunology ; Hepatitis C/*epidemiology ; Hepatitis C Antibodies/*blood ; Humans ; Male ; Middle Aged ; Republic of Korea ; Rural Population ; Seroepidemiologic Studies ; Urban Population